Change in Novo Nordisk Executive Management
(Thomson Reuters ONE) -
Bagsværd, Denmark, 1 March 2017 - Novo Nordisk A/S today announced that Jakob
Riis, executive vice president, head of North America Operations and president
of Novo Nordisk Inc. has resigned from the company.
Effective today, Doug Langa, senior vice president for Market Access, Novo
Nordisk Inc., has been appointed senior vice president, head of North America
Operations and president of Novo Nordisk Inc. He will report to Lars Fruergaard
Jørgensen, president and CEO, Novo Nordisk A/S.
Jakob Riis will remain with Novo Nordisk in a transition period to help ensure a
smooth handover.
Göran Ando, chairman of the Board of Directors of Novo Nordisk A/S, said: "We
are of course sad to see Jakob Riis leave. He has done a great job throughout
his career in Novo Nordisk, and we wish him all the best. We welcome Doug Langa
as our new head of North America Operations. Doug's experience in the US
pharmaceutical market, his leadership skills and expertise in the area of market
access make him the natural successor to Jakob Riis."
Doug Langa is senior Vice president, Market Access and a member of Novo
Nordisk's US leadership team. He joined the company in 2011 as senior director,
Managed Markets. He came from GlaxoSmithKline where he was senior director of
Payer Marketing. Prior to GSK, Doug Langa spent the majority of his career at
Johnson & Johnson, where he held various roles of increasing responsibility
within Managed Markets, Sales Leadership and Marketing. He has over 25 years of
experience in the pharmaceutical and medical device industry. He graduated from
Widener University and earned his MBA from Fordham University.
Further information
Media:
Anne Margrethe Hauge +45 3079 3450 amhg(at)novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Hanna Ögren +45 3079 8519 haoe(at)novonordisk.com
Anders Mikkelsen +45 3079 4461 armk(at)novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj(at)novonordisk.com
Company announcement No 16 / 2017
CA170301_change_executive_management_UK:
http://hugin.info/2013/R/2083204/785208.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.03.2017 - 07:17 Uhr
Sprache: Deutsch
News-ID 527387
Anzahl Zeichen: 2930
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Change in Novo Nordisk Executive Management"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
